Please assess the completion status of the following clinical trial:

Trial Title: A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy children and adolescents aged 3-17 years old.~2. Informed consent obtained and signed by subjects or legal guardians prior to screening. Children or adolescents aged 10-17 yrs need sign informed consent by themselves.~3. Willing to participate for the planned duration of the study, including availability for follow-up.~Exclusion Criteria:~1. Any investigational or unregistered product (drug, vaccine or device) was used within 30 days, or planned to be used during the trial.~2. have been vaccinated with any influenza vaccine within 6 months, or plan to be vaccinated during the trail.~3. Immunosuppressive agents or other immunomodulatory drugs (defined as continuous use for more than 14 days) were used over a 3-month period.~4. Immunoglobulins and / or any blood products were used within 3 months, or planned to be used before blood collection.~5. History of Guillain-Barré syndrome; History of hypersensitivity to any component of the LAIV, including egg or egg products.~6. Severe allergic reactions after vaccination (including anaphylactic shock, allergic laryngeal edema, allergic purpura, local allergic necrosis).~7. Acute diseases , infections or febrile diseases (axillary temperature ≥37.1℃) on the day of vaccination.~8. Obvious coagulation dysfunction or History of anticoagulant therapy~9. Aspirin is being used(Salicylates are a potential risk factor for Reye syndrome)~10. Known or suspected immune deficiency diseases or immunosuppressed~11. Heart disease, respiratory diseases (including severe rhinitis, nasal deformities, polyps, etc.), liver disease, kidney disease, mental disorders, chronic infections etc.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- LAIV (Type: EXPERIMENTAL): a single dose of Live-Attenuated influenza Vaccine;Dose: 0.2 ml; Each dose contains not less than 6.9 lg EID50 of type A live attenuated influenza virus reassortants(H1N1 and H3N2), and not less than 6.4 lg EID50 of type B live attenuated influenza virus reassortants.
- Placebo (Type: PLACEBO_COMPARATOR): a single dose of Placebo. Inactivated placebo will be identical to LAIV in appearance, ingredients and concentrations, attenuated influenza virus free.

Based on this trial design, predict the completion outcome and termination type (if applicable).